© The Author 2016. Published by Oxford University Press on behalf of the British Geriatrics Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits noncommercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

High serum adiponectin levels predict incident falls among middle-aged and older adults: a prospective cohort study

Cong Huang¹, Haruki Momma¹, Kaijun Niu², Masahiko Chujo³, Atsushi Otomo³, Yufei Cui¹, Ryoichi Nagatomi¹

¹Division of Biomedical Engineering for Health and Welfare, Tohoku University Graduate School of Biomedical Engineering, Sendai, Japan

²Department of Epidemiology, School of Public Health, Tianjin Medical University, Tianjin, China

³Department of Medicine and Science in Sports and Exercise, Tohoku University Graduate School of Medicine, Sendai, Japan

Address correspondence to: R. Nagatomi. Tel/Fax: (+81) 22 717 8586. Email: nagatomi@med.tohoku.ac.jp

Abstract

Background and objective: adiponectin is an adipocyte-derived hormone with anti-obesity and anti-diabetic properties. However, higher circulating adiponectin levels are related to poor muscle function and physical disability, which suggests a potential link between adiponectin and risk of falls. Nevertheless, no direct association between circulating adiponectin levels and incident fall risk has been reported. Therefore, this study aimed to investigate the relationship between serum adiponectin levels and incident falls in a population of middle-aged and older adults.

Design: a prospective cohort study.

Setting: Oroshisho Center in Sendai City, Japan.

Subjects: Japanese adults who were \geq 45 years old (*n* = 430).

Measurements: serum adiponectin levels were measured at baseline, and the subjects were divided into sex-specific tertiles. Data regarding a history of falls were collected via participant recall using a self-reported questionnaire. Incident falls were defined as falls that were experienced by people without a history of falls at baseline.

Results: during the 2-year follow-up, 15.6% (67/430) of the subjects experienced an incident fall. In the univariate logistic regression analysis, incident falls were significantly more frequent across the increasing sex-specific serum adiponectin tertiles (*P* for trend = 0.008). Adjusted odds ratios (95% confidence interval) for incident falls were 2.31 (1.07–4.98) in the middle tertile and 3.61 (1.63–7.99) in the highest tertile; this risk was significantly higher than that for the lowest adiponectin tertile (*P* for trend = 0.002).

Conclusions: the findings of this prospective cohort study indicate that higher serum adiponectin levels may be a predictor of incident falls.

Keywords: adiponectin, fall risk, biomarker, prevention, geriatrics

Introduction

Adiponectin is an adipocyte-derived hormone that is considered beneficial to human health, due to its positive effect on metabolic syndrome and type II diabetes [1]. Studies have demonstrated that adiponectin may protect against these metabolic diseases via its effect on fatty acid utilisation and promoting insulin sensitivity [2]. However, in middle-aged and older adults, circulating adiponectin levels increase with age, and these increased levels have been proposed as an indicator for the incidence of cardiovascular disease [3, 4] and mortality [3–5]. The potentially paradoxical role of adiponectin in physical function has also been reported in a previous prospective study, which found that higher circulating

Prediction of incident falls among older adults through high serum adiponectin levels

adiponectin levels contributed to the increased incidence of physical disability among the elderly subjects [5]. Moreover, growing amounts of evidence from population-based crosssectional studies reveal that circulating adiponectin levels are associated with several factors that indicate a poor health status, such as decreased muscle strength [6], low bone mineral density [7] and poor nutrition status [5]. As all of these factors are strong determinants of falls [8–10], it is possible that there is a correlation between circulating adiponectin levels and the risk of falling. However, no study has examined whether adiponectin levels accurately predict incident falls.

In Japan, the fall rate for people who are ≥ 65 years old is 12.8% for men and 21.5% for women [11]. As a geriatric syndrome, falls occur in one-third of community-dwelling older adults aged 72 years and older in America [12], and these falls are responsible for $\sim 70\%$ of all unintentional injuries that are observed in this population [13, 14]. Moreover, fall-induced injuries are one of the common causes of disability [15] and mortality [16], and contribute to $\sim 5\%$ of the total healthcare and long-term care costs in Japan [17]. As in the older population, falls among middle-aged adults are also an important source of fatal and non-fatal injuries [18]. Therefore, falls in both middle-aged and older people have become a serious public health problem.

Although these epidemiological observations suggest a possible correlation between circulating adiponectin levels and incident falls among older people, no previous studies have examined this topic. Therefore, this prospective cohort study aimed to investigate the relationship between circulating adiponectin levels and the risk of incident falls in a population of middle-aged and older adults.

Methods

Study participants

The data for the present study were obtained during the Oroshisho Study, which was a prospective cohort study of the lifestyle-related effects on illnesses and health status among Japanese adult employees who were working at the Sendai Oroshisho Center (Sendai, Japan), which is a group composed of >120 small and medium enterprises, between 2008 and 2011. In the present study, a 2-year prospective cohort study was designed to evaluate data from 2009 to 2011, as data from this period included information regarding falls. In 2009, 1,263 participants received an annual health examination, which was performed during the second week of August. Among these participants, 1,215 employees provided their informed consent for the analyses that were planned for this study. Based on the higher prevalence of fall-related injuries among middle-aged and older people [13, 18], only participants who were \geq 45 years old were included in the current study, which yielded a sample of 642 subjects. The exclusion criteria included missing data regarding baseline serum adiponectin (n = 1) or covariates (n = 33), a history of falls at baseline (n = 78) and missing data regarding incident falls at 2-year follow-up (n = 100). Based on these exclusions, 430

adults who were \geq 45 years old (349 men) met the inclusion criteria for this study. Approval for the study was obtained from the institutional review board of Tohoku University Graduate School of Medicine.

Serum adiponectin measurements

Serum adiponectin levels were assessed under overnight fasting conditions using a specific sandwich enzyme-linked immunosorbent assay (Otsuka Pharmaceutical, Tokyo, Japan). The lower limit of detection for this assay was 23.4 ng/l, the detection range was 0.375-12.0 ng/ml and the intra- and inter-assay coefficients of variation were <10%. Adiponectin levels were divided into sex-specific tertiles, based on their distribution in the statistical analysis.

Measuring the incidence of falls

The self-reported experience of falls was measured at baseline (2009) and at the follow-up (2010–11) by asking 'Did you have any falls in the previous year?'. The answers to this question consisted of yes or no, and participants were questioned regarding the number of falls they experienced. In this study, incident fall was defined as any fall that was experienced during 2010–11.

Relevant covariates

Sociodemographic data (sex, age, occupation, educational levels and marital status), smoking status and drinking frequency were collected using a self-administered survey. Estimated daily intakes of energy and protein during the preceding month were calculated using an *ad hoc* computer program and data from the brief self-administered dietary history questionnaire, which contains questions regarding the frequency at which 75 principal foods are consumed [19]. Physical activity (PA) was assessed using the International Physical Activity Questionnaire [20]. Moderate PA was defined as ≥ 23 metabolic equivalent (MET) hours per week, which is the reference quantity for exercise, PA and fitness levels to prevent lifestyle-related diseases, as recommended by the Japanese Ministry of Health, Labour, and Welfare [21]. Anthropometric factors (height and body weight) were recorded, and the subject's body mass index (BMI) was calculated as weight $(kg)/height^2 (m^2)$.

Several health-related variables were also examined. Using a quantitative ultrasound device (AOS-100; Aloka Co, Tokyo, Japan), the osteo-sono assessment index (OSI) of the right calcaneus was measured as an indicator of bone mineral density [22]. OSI was calculated using the equation: $OSI = TI \times SOS^2$, where TI is the transmission index and SOS is the speed of sound. As an inflammatory marker, serum high-sensitivity C-reactive protein (hs-CRP) levels were measured using the N-latex CRP-2 assay (Siemens Healthcare Japan, Tokyo, Japan). Depressive symptoms were assessed using the Japanese version of the self-rated depression scale (SDS) [23]. Participants with a total SDS score of \geq 45 were considered to have depressive symptoms [24]. Metabolic syndrome was defined based on the

C. Huang et al.

American Heart Association Scientific Statement criteria for individuals of Asian ethnicity (including Japanese people) [25]. Regarding the components of metabolic syndrome, waist circumference was measured according to a standardised protocol, and sitting blood pressure was measured at rest, using the upper right arm and an automatic device (Yamasu 605P; Kenzmedico, Saitama, Japan). Enzymatic methods were used with the appropriate kits to determine serum levels of fasting glucose (Eurotec, Tokyo, Japan), triglycerides and high-density lipoprotein-cholesterol (Sekisui Medical, Tokyo, Japan).

Statistical analysis

All continuous variables in this study were log-transformed prior to statistical analysis because of their skewed distribution, and then re-transformed for data presentation. Participants' characteristics according to the sex-specific serum adiponectin tertiles were analysed using analysis of variance for continuous variables and the χ^2 test for categorical variables. Data were expressed as means or estimated geometric means (95% confidence interval, CI) or percentages, as appropriate.

To determine the relationship between baseline adiponectin levels and incident falls during the follow-up period, logistic regression analysis was used to calculate the odds ratio (95% CI) for incident falls in each adiponectin tertile, using the lowest adiponectin tertile as the reference group. Multivariate analyses were divided into three statistical models, with Model 1 being

adjusted for BMI and the sociodemographic variables, which included sex, age, occupation (desk work or not), educational level (≥college or not) and marital status (married or not). In addition to the covariates in Model 1, Model 2 included lifestyle-related variables, such as smoking status (never, former, current), drinking frequency (never, sometimes, every day), daily energy and protein intake, and PA (≥23 MET h/week). In addition to the covariates in Model 2, Model 3 included health status variables (OSI, hs-CRP, depressive symptoms and metabolic syndrome). An age-stratified analysis of the association between adiponectin and falls risk was also performed. In addition, cross-product terms were created to examine the interactions between serum adiponectin levels and each covariate for incident falls, and these were added to the regression model. All tests were two-tailed, and P values of <0.05 were considered statistically significant. All analyses were performed using SPSS software (version 22.0; SPSS Inc., Chicago, IL, USA).

Results

Participants' characteristics

The mean age (SD) for the study sample was 54.9 (6.3) years (range, 45–83 years), and the proportion of subjects who were \geq 55 years old (pre-elderly and older) was 52.1%. In this study, 81.2% of the subjects (349/430) were men. Similar characteristics were observed when we compared the subjects who

Table I. Baseline participants' characteristics according to sex-specific serum adiponectin tertiles

Variables	Sex-specific serum adiponectin tertiles			
	145 (28 women)	143 (26 women)	142 (27 women)	
Adiponectin range, mg/l	Men: 1.0–5.2	Men: 5.3–7.8	Men: 7.9–27.6	
	Women: 2.5–9.0	Women: 9.1–12.5	Women: 12.6–24.4	
Age, years ^a	54.2 (53.1-55.1)	53.6 (52.7-54.7)	55.8 (54.8-56.9)	0.03
BMI, kg/m ^{2a}	24.4 (23.9–24.9)	22.7 (22.2–23.2)	22.2 (21.7-22.7)	< 0.001
Education (≥college), %	29.7	29.4	26.1	0.76
Occupation (desk work), %	85.5	82.5	78.2	0.26
Marital status (married), %	82.1	86.0	83.8	0.66
Smoking status				
Current, %	41.4	47.6	34.5	
Former, %	13.1	9.8	11.3	
Never, %	45.5	42.7	54.2	0.25
Drinking frequency				
Every day, %	34.5	37.1	40.8	
Sometimes, %	40.7	42.7	38.7	
Never, %	24.8	20.3	20.4	0.88
Energy intake, kcal/day ^a	1,876 (1,776-1,980)	1,806 (1,710-1,908)	1,797 (1,701-1,899)	0.28
Protein intake, g/day ^a	64.0 (60.0-68.4)	61.7 (57.8-66.0)	62.7 (58.7-67.0)	0.67
PA ≥23 MET h/week, %	35.2	39.2	43.7	0.34
High-sensitivity CRP, mg/l ^a	0.5 (0.4-0.6)	0.4 (0.3–0.5)	0.3 (0.2–0.3)	< 0.001
OSI, arbitrary units ^a	2.7 (2.6–2.7)	2.6 (2.6–2.7)	2.6 (2.6–2.7)	0.06
Metabolic syndrome, %	49.0	25.2	16.2	< 0.001
Depressive symptoms, %	39.3	33.6	33.1	0.47

The significance of bold values were defined as a P value <0.05.

Data are presented as mean (95% confidence interval), percentage or range.

BMI, body mass index; CRP, C-reactive protein; MET, metabolic equivalent; PA, physical activity; OSI, osteo-sono assessment index.

^aVariables were log-transformed due to a skewed distribution.

*Differences were evaluated using ANOVA and the χ^2 test, as appropriate.

Prediction of incident falls among older adults through high serum adiponectin levels

did and did not complete the follow-up (Supplementary data, Table S1, available in *Age and Ageing* online). A significant sexrelated difference was observed in the adiponectin levels, with women having higher levels than men. Table 1 shows the participants' baseline characteristics according to the sex-specific adiponectin tertiles. Mean age increased significantly with the

Table 2. Multivariate logistic regression analysis of the association between baseline sex-specific serum adiponectin tertiles and the incidence of falls at follow-up

	Odds ratio (95% confidence interval) for incident falls			
	Model 1 ^a	$Model2^{\rm b}$	Model 3 ^c	
•••••	•••••		• • • • • • • • •	
Sex-specific serum adip	onectin tertiles			
Tertile 1 (Reference)	1	1	1	
Tertile 2	2.14 (1.01-4.52)*	2.17 (1.02-4.61)*	2.31 (1.07-4.98)*	
Tertile 3	3.10 (1.47-6.53) [†]	3.36 (1.57-7.18) [†]	3.61 (1.63-7.99) [†]	
P for trend	0.003	0.002	0.002	

The significance of bold values were defined as a P value <0.05.

^aAdjusted for, sex, log age, occupation (desk work), marital status (married), education level (≥college) and log body mass index.

^bAdjusted for smoking status (current, former, never), drinking frequency (every day, sometimes, never), log daily energy intake, log daily protein intake, physical activity (≥23 metabolic equivalent h/week) and the variables in Model 1.

^cAdjusted for log osteo-sono assessment index, log high-sensitivity C-reactive protein, depressive symptoms, metabolic syndrome and the variables in Model 2. *P < 0.05.

 $^{\dagger}P < 0.01.$

increasing adiponectin tertiles (P < 0.05). In contrast, adiponectin levels were inversely associated with BMI, hs-CRP and the prevalence of metabolic syndrome (P < 0.001). In addition, participants with higher adiponectin levels tended to have lower OSI, although the difference was not significant (P = 0.06). The sex-specific adiponectin tertiles were not correlated with the other variables at baseline. During the 2-year follow-up, 15.6% of the subjects (67/430) experienced at least one incident fall.

Serum adiponectin levels and the incidence of falls

Univariate logistic regression analysis (Supplementary data, Figure S1, available in *Age and Ageing* online) revealed a graded relationship between adiponectin levels and the risk of falls (odds ratio [95% CI]: Tertile 2, 1.79 [0.88–3.64]; Tertile 3, 2.51 [1.27–4.96], *P* for trend = 0.008). Multivariate analysis confirmed that this linear trend was detected in all three covariates-adjusted models (*P* for trend <0.01) (Table 2). In the fully adjusted model (Model 3), the risk of incident falls in the second and third adiponectin tertiles were 2.3-fold and 3.6-fold higher, respectively, than that in the first tertile (odds ratio [95% CI]: Tertile 2, 2.31 [1.07–4.98], *P* < 0.05; Tertile 3, 3.61 [1.63–7.99], *P* < 0.01). No significant interactions between adiponectin levels and the other covariates for incident falls were observed (data not shown). Moreover, an age-stratified analysis revealed that higher

 Table 3. Age-stratified analysis of the association between baseline sex-specific serum adiponectin tertiles and the incidence of falls at follow-up

	Odds ratio (95% confidence into	Odds ratio (95% confidence interval) for incident falls			
	Model 1 ^a	Model 2 ^b	Model 3 ^c		
Younger middle-aged adults (45–54 year	ars old)				
Sex-specific serum adiponectin tertiles	(n = 206)				
No. of participants	70 (15 women)	69 (15 women)	67 (13 women)		
Tertile 1 (Reference) ^d	1	1	1		
Tertile 2	1.38 (0.48-3.93)	1.32 (0.45-3.90)	1.05 (0.34-3.25)		
Tertile 3	2.98 (1.06-8.38)*	3.12 (1.06–9.14)*	2.53 (0.81-7.88)		
P for trend	0.032	0.030	0.079		
Pre-elderly and older (\geq 55 years old)					
Sex-specific serum adiponectin tertiles	(n = 224)				
No. of participants	75 (13 women)	75 (13 women)	74 (12 women)		
Tertile 1 (Reference) ^e	1	1	1		
Tertile 2	2.81 (0.95-8.35)	3.08 (0.99-9.54)	3.68 (1.13-12.0)*		
Tertile 3	3.20 (1.10-9.34)*	3.38 (1.11–10.3)*	5.27 (1.54–18.0) [†]		
<i>P</i> for trend	0.037	0.036	0.008		

The significance of bold values were defined as a P value <0.05.

 a Adjusted for sex, log age, occupation (desk work), marital status (married), education level (\geq college) and log body mass index.

^bAdjusted for smoking status (current, former, never), drinking frequency (every day, sometimes, never), log daily energy intake, log daily protein intake, physical activity (≥23 metabolic equivalent h/week) and the variables in Model 1.

^cAdjusted for log osteo-sono assessment index, log high-sensitivity C-reactive protein, depressive symptoms, metabolic syndrome and the variables in Model 2.

^dAdiponectin range (mg/l) in younger middle-aged men (Tertile 1: 1.0–5.0, Tertile 2: 5.1–7.0, Tertile 3: 7.1–20.9) and women (Tertile 1: 2.5–6.9, Tertile 2: 7.0–12.3, Tertile 3: 12.4–24.3).

^eAdiponectin range (mg/l) in pre-elderly and older men (Tertile 1: 1.1–5.3, Tertile 2: 5.4–8.1, Tertile 3: 8.2–27.6) and women (Tertile 1: 3.7–9.0, Tertile 2: 9.1–12.5, Tertile 3: 12.6–24.4).

*P < 0.05.

 $^{\dagger}P < 0.01.$

C. Huang et al.

adiponectin levels were significantly associated with increased risk of incident falls in pre-elderly and older people (\geq 55 years old) (odds ratio [95% CI]: Tertile 2, 3.68 [1.13–12.0]; Tertile 3, 5.27 [1.54–18.0], *P* for trend = 0.008) (Table 3).

Discussion

In this prospective study of adults who were \geq 45 years old, subjects with higher levels of serum adiponectin tended to have a higher incidence of falls, compare with subjects with lower levels of circulating adiponectin. To our knowledge, the present study is the first to investigate the relationship between circulating adiponectin levels and the risk of falling, and our findings indicate that adiponectin levels were associated with the incidence of falls.

Despite there being no direct evidence in the literature for comparison, the findings of a few previous studies may partially support our observed association between adiponectin and incident falls. For example, one prospective study noted that higher serum adiponectin levels predicted incident physical disability, which was defined as experiencing difficulty in the activities of daily living and impaired mobility [5]. Most recently, our cross-sectional study of Japanese elderly found that high serum adiponectin levels were independently associated with decreased lower extremity muscle strength [6]. Loncar et al. [26] have also reported an inverse association between circulating adiponectin levels and muscle strength or muscle mass in 73 elderly patients with chronic heart failure. Thus, the contribution of adiponectin to incident falls in this study appears to extend the findings of these previous studies, as it is well known that the most common risk factor for falls is muscle weakness [20].

To examine the potential mechanisms underlying the relationship between adiponectin levels and incident falls, we added various PA and health status factors to our regression model, which included nutrition status (BMI, and daily energy and protein intakes), depressive symptoms, OSI, hs-CRP and metabolic syndrome. However, adjusting for these covariates did not change our findings, which suggests that these factors did not account for the relationship between adiponectin levels and incident falls. Alternatively, elderly people with low muscle strength or muscle mass have an increased risk of falls [8, 27], as declines in lower extremity muscle strength can result in loss of balance [28], and this factor may partially explain our findings. Thus, muscle weakness could be considered an essential confounding factor when performing further studies regarding the association between adiponectin levels and the incidence of falls.

One strength of the present study is the use of a prospective study design, which allowed us to assess the predictive value of adiponectin levels. Another strength is that our analysis was limited to subjects who did not have a history of falls at baseline. This is very important for evaluating the risk of incident falls, as a history of falls is a strong predictor of recurrent falls [29]. However, several limitations of the present study should also be considered. First, interpretations of our observations are limited by the lack of assessment regarding any potential mechanism(s), which include lower extremity skeletal mass and muscle strength. Further, falls assessment was performed using a self-reported questionnaire, which is subject to recall bias. In addition, detailed information regarding the date, location and cause of the falls could not be recorded. Finally, interpretation of the sex-stratified analysis in this study is complicated by the relatively small number of female subjects.

In conclusion, this population-based study is the first to provide evidence regarding the relationship between adiponectin levels and the risk of falls. At the 2-year follow-up, higher baseline serum adiponectin levels predicted a greater incidence of falls in a population of predominantly middle-aged and pre-elderly individuals. These findings suggest that adiponectin may be a useful biomarker for the incidence of falls. In the scientific literature regarding the prevention of falls and fallrelated injuries, there seems to be evidence that supports the effectiveness of preventive measure. It is noteworthy that more attention should be paid to the potential role of adiponectin in physical health. Further prospective studies with different populations and a longer follow-up period are needed to confirm the association between adiponectin levels and the risk of falls, and to assess the potential mechanisms underlying these observations.

Key points

- A 2-year incidence of falls was 12.5% in predominantly middle-aged and pre-elderly individuals.
- Subjects with higher circulating levels of adiponectin tended to have increased risk of falls.
- Nutrition status, bone health and mental disorders could not explain the association between adiponectin levels and falls risk.

Supplementary data

Supplementary data mentioned in the text are available to subscribers in *Age and Ageing* online.

Acknowledgements

We thank the study participants who consented to the data analysis and the staff from the Oroshisho Study.

Conflicts of interest

None declared.

Funding

This study was supported by a Grant-in-Aid under the Knowledge Cluster Initiative from the Ministry of Education, Culture, Sports, Science and Technology of Japan and partially supported by the Center of Innovation Program from Japan Science and Technology Agency, JST. The funding sources

Prediction of incident falls among older adults through high serum adiponectin levels

had no involvement in study design, execution, analysis and interpretation of data, or writing of the study.

References

- **1.** Choi KM, Lee J, Lee KW *et al.* Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 2004; 61: 75–80.
- **2.** Yamauchi T, Kamon J, Waki H *et al.* The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941–6.
- **3.** Dekker JM, Funahashi T, Nijpels G *et al.* Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489–96.
- **4.** Wannamethee SG, Welsh P, Whincup PH *et al.* High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur J Cardiovasc Prev Rehabil 2011; 18: 65–71.
- **5.** Kizer JR, Arnold AM, Strotmeyer ES *et al.* Change in circulating adiponectin in advanced old age: determinants and impact on physical function and mortality. The Cardiovascular Health Study All Stars Study. J Gerontol A Biol Sci Med Sci 2010; 65: 1208–14.
- 6. Huang C, Tomata Y, Kakizaki M *et al.* High circulating adiponectin levels predict decreased muscle strength among older adults aged 70 years and over: a prospective cohort study. Nutr Metab Cardiovasc Dis 2015; 25: 594–601.
- Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, Mohiti A. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab 2014; 32: 400–4.
- **8.** Landi F, Liperoti R, Russo A *et al.* Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 2012; 31: 652–8.
- 9. Lin MR, Hwang HF, Lin PS, Chen CY. Relations of osteoporosis and follow-up duration to recurrent falls in older men and women. Osteoporosis Int 2014; 25: 863–71.
- Vivanti AP, McDonald CK, Palmer MA, Sinnott M. Malnutrition associated with increased risk of frail mechanical falls among older people presenting to an emergency department. Emerg Med Australas 2009; 21: 386–94.
- Yasumura S, Haga H, Nagai H, Suzuki T, Amano H, Shibata H. Rate of falls and the correlates among elderly people living in an urban-community in Japan. Age Ageing 1994; 23: 323–7.
- Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. N Engl J Med 1997; 337: 1279–84.
- **13.** Stel VS, Smit JH, Pluijm SMF, Lips P. Consequences of falling in older men and women and risk factors for health service use and functional decline. Age Ageing 2004; 33: 58–65.
- 14. Talbot LA, Musiol RJ, Witham EK, Metter EJ. Falls in young, middle-aged and older community dwelling adults: perceived

cause, environmental factors and injury. BMC Public Health 2005; 5: 86.

- **15.** Gill TM, Allore HG, Holford TR, Guo ZC. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004; 292: 2115–24.
- Paulozzi LJ, Ballesteros MF, Stevens JA. Recent trends in mortality from unintentional injury in the United States. J Safety Res 2006; 37: 277–83.
- **17.** Hayashi Y. Prevention of the falls in the elderly. Nihon Ronen Igakkai Zasshi 2007; 44: 591–4 (in Japanese).
- Vyrostek SB, Annest JL, Ryan GW. Surveillance for fatal and nonfatal injuries—United States, 2001. MMWR Surveill Summ 2004; 53: 1–57.
- Kobayashi S, Honda S, Murakami K *et al.* Both comprehensive and brief self-administered diet history questionnaires satisfactorily rank nutrient intakes in Japanese adults. J Epidemiol 2012; 22: 151–9.
- **20.** Craig CL, Marshall AL, Sjostrom M *et al*. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381–95.
- **21.** Ishikawa-Takata K, Tabata I. Exercise and physical activity reference for health promotion 2006 (EPAR2006). J Epidemiol 2007; 17: 177.
- **22.** Tsuda-Futami E, Hans D, Njeh CF *et al.* An evaluation of a new gel-coupled ultrasound device for the quantitative assessment of bone. Br J Radiol 1999; 72: 691–700.
- Fukuda K, Kobayashi S. A study on a self-rating depression scale (authors transl). Seishin Shinkeigaku Zasshi 1973; 75: 673–9 (in Japanese).
- **24.** Fountoulakis KN, lacovides A, Samolis S *et al.* Reliability, validity and psychometric properties of the Greek translation of the Zung Depression Rating Scale. BMC Psychiatry 2001; 1: 6.
- 25. Alberti KG, Eckel RH, Grundy SM *et al.* Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–5.
- **26.** Loncar G, Bozic B, von Haehling S *et al.* Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur J Intern Med 2013; 24: 818–23.
- 27. Rubenstein LZ, Josephson KR. The epidemiology of falls and syncope. Clin Geriatr Med 2002; 18: 141–58.
- **28.** Chan BKS, Marshall LM, Winters KM, Faulkner KA, Schwartz AV, Orwoll ES. Incident fall risk and physical activity and physical performance among older men The Osteoporotic Fractures in Men Study. Am J Epidemiol 2007; 165: 696–703.
- **29.** Wolfson L, Judge J, Whipple R, King M. Strength is a major factor in balance, gait, and the occurrence of falls. J Gerontol A Biol Sci Med Sci 1995; 50: 64–7.

Received 14 August 2015; accepted in revised form 23 December 2015